Related Experiment Video
Updated: May 29, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Restrictions on interactions between doctors and industry could ultimately hurt patients
1Cardiac Catheterization Laboratory and Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA. ckimmelstiel@tuftsmedicalcenter.org
Abstract:
Physician-industry collaboration has led to a diverse array of therapeutic advancements that have benefitted a broad spectrum of patient populations. Evolving regulations, both institutional and governmental, aiming to govern interactions between physicians and pharmaceutical and medical device manufacturers have become increasingly prevalent. Emerging data suggest that restrictions on physician-industry collaboration have the potential to harm patient care by degrading innovation and stifling medical education. The following article reviews the effects of legislation on medical innovation as well as the impact on continuing medical education.
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Ethical Standards II
Nurses are entrusted with upholding various ethical principles and standards. Nurses forge solid therapeutic relationships using trust, empathy, autonomy, confidentiality, and professional competence.
Confidentiality is crucial, embodying respect for individual privacy and...
Ethical Issues
Ethical Concerns in Healthcare:
Nurses' Legal Responsibilities II
Communication between nurses and patients...
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
